Avalyn Pharma is a biotechnology company focused on developing innovative, targeted inhaled therapies for rare respiratory diseases, particularly idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). With a recent oversubscribed $175M Series C financing, Avalyn is advancing its clinical-stage portfolio, which includes inhaled formulations of FDA-approved antifibrotics such as pirfenidone and nintedanib. The company aims to improve patient outcomes by providing inhaled alternatives that are better tolerated than traditional oral medications, thereby addressing the significant side effects that affect 30-50% of patients. Avalyn's lead product, AP01, has shown promising results in clinical studies, demonstrating efficacy and safety in patients with pulmonary fibrosis.